ArticleJournal of global health2026
Long-term risk of incident psoriasis in patients with irritable bowel syndrome: a large-scale prospective cohort study.
Article in Journal of global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While irritable bowel syndrome (IBS) and psoriasis share some pathophysiological features, it remains unclear whether they are associated with one another. Therefore, we aimed to investigate the long-term risk of incident psoriasis in a large prospective cohort of patients with IBS. Methods: We retrieved data on 437,170 participants from the UK Biobank without psoriasis at baseline. Using ICD-10 codes, we classified these participants into IBS and non-IBS groups based on recruitment status and assessed them for incident psoriasis at follow-ups as the primary outcome. We used multivariable Cox proportional hazards models to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). Results: We identified 21,748 (5.0%) IBS patients among the 437,170 participants. There were 4325 (1.0%) incident psoriasis cases during a median follow-up period of 14.4 years, amounting to a cumulative incidence of 0.88% (95% CI = 0.73-1.02) in the IBS group vs. 0.69% (95% CI = 0.66-0.72) in the non-IBS group. Compared with non-IBS patients, patients with IBS had a 35.0% higher risk of developing psoriasis (HR = 1.35; 95% CI = 1.19-1.52). In subgroup analyses, a higher psoriasis risk associated with IBS was generally observed across age, sex, Townsend deprivation index, smoking status, non-steroidal anti-inflammatory drug use, C-reactive protein, and polygenic risk score of psoriasis subgroups. Conclusions: The IBS patients in our sample had an increased long-term risk of incident psoriasis. This finding highlights the importance of monitoring psoriasis in IBS patients and suggests a potential shared pathophysiological mechanism between the two conditions which may inform future preventive and therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.